$CRDF

Investing.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).

Cardiff Oncology (NASDAQ:CRDF) announced a registered direct offering expected to raise about $10 million in gross proceeds. The deal includes 8,571,429 shares at $1.05 per share plus warrants, with officers and directors buying 731,707 shares at $1.435. Net proceeds will fund working capital and general corporate purposes. Closing is expected around July 16, 2026.

PACE GARY W purchased 687,285 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 ($1.00M total) on 2026-07-14.

Mohindru Mani (Chief Executive Officer) purchased 34,364 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 on 2026-07-14.

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 crdf-ex10_1.htm EX-10.1 EX-10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 14, 2026, between Cardiff Oncology, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the signature p

Cardiff Oncology (Nasdaq: CRDF) announced a $10 million registered direct offering. It will sell 8,571,429 common shares with warrants at $1.05 per share, plus insider participation of 731,707 shares at $1.435 per share. Warrants exercise at $1.31, exercisable after six months and stockholder-authorized share increase. Closing expected July 16, 2026.

Mohindru Mani (Chief Executive Officer) purchased 24,703 shares of Cardiff Oncology, Inc. (CRDF) at $1.21 on 2026-06-18.

PACE GARY W purchased 30,000 shares of Cardiff Oncology, Inc. (CRDF) at $1.22 on 2026-06-18.

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001213037 false 0001213037 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,

Cardiff Oncology, Inc. (CRDF) has filed a lawsuit against Nerviano Medical Sciences S.r.L (NMS) to dispute an alleged material breach of their license agreement for the drug onvansertib. NMS claimed breach because Cardiff Oncology did not name an NMS employee as a joint inventor on certain patents and would not agree to file a joint invention continuation patent application. Cardiff Oncology maintains that it did not breach the agreement and that the agreement does not require naming NMS employees on inventions made exclusively by Cardiff Oncology.